Loss of PPT1/CLN1 function | Sample | Affected gene/protein | Reference |
Ppt1/Cln1−/− | Brain tissues and cells from a Ppt1/Cln1−/− mouse | Increased expression of CtsD/Cln10 | Chandra et al., 2015 [87] |
Ppt1/Cln1−/− | Brain tissues and cells from a Ppt1/Cln1−/− mouse | Reduced maturation of CTSD/CLN10 to its enzymatically active form | Chandra et al., 2015 [87] |
Loss of TPP1/CLN2 function | Sample | Affected gene/protein | Reference |
Tpp1/Cln2−/− | Brain tissues from a Tpp1/Cln2−/− mouse | Increased expression of CtsD/Cln10 | Domowicz et al., 2019 [88] |
Tpp1/Cln2−/− | Brain tissues from a Tpp1/Cln2−/− mouse | Increased expression of Pgrn/Cln11 | Domowicz et al., 2019 [88] |
Loss of CLN3 function | Sample | Affected gene/protein | Reference |
CLN3 (mutated) | CLN3 disease patient fibroblasts | Reduced amount of PPT1/CLN1 in lysosomes, which correlated with reduced enzymatic activity | Appu et al., 2019 [89] |
Cln3Δex7/8 | Mouse brain cortex from a Cln3Δex7/8 mouse | Reduced amount of PPT1/CLN1 in lysosomes, which correlated with reduced enzymatic activity | Appu et al., 2019 [89] |
Cln3Δex7/8 | Cerebellar cells from a Cln3Δex7/8 mouse | Increased amount of PPT1/CLN1 in lysosomes, which correlated with increased enzymatic activity | Schmidtke et al., 2019 [90] |
Cln3Δex7/8 | Cerebellar cells from a Cln3Δex7/8 mouse | Increased amount of TPP1/CLN2 in lysosomes | Schmidtke et al., 2019 [90] |
Cln3Δex7/8 | Cerebellar cells from a Cln3Δex7/8 mouse | Decreased amount of CLN5 in lysosomes | Schmidtke et al., 2019 [90] |
Cln3Δex7/8 | Cerebellar cells from a Cln3Δex7/8 mouse | Decreased amount of CTSD/CLN10 in lysosomes | Schmidtke et al., 2019 [90] |
Loss of DNAJC5/CLN4 function | Sample | Affected gene/protein | Reference |
DNAJC5/CLN4 (mutated) | CLN4 disease patient brain | Increased amount of PPT1/CLN1 | Henderson et al., 2016 [81] |
DNAJC5/CLN4 (mutated) | CLN4 disease patient brain | Reduced enzymatic activity of PPT1/CLN1, which resulted in its mis-localization | Henderson et al., 2016 [81] |
Loss of CLN5 function | Sample | Affected gene/protein | Reference |
CLN5 (mutated) | CLN5 disease patient fibroblasts | Increased activity of TPP1/CLN2 | Vesa et al., 2002 [77] |
Loss of MFSD8/CLN7 function | Sample | Affected gene/protein | Reference |
Mfsd8/Cln7−/− | Embryonic fibroblasts from a Mfsd8/Cln7−/− mouse | Reduced amount of CLN5 in lysosomes | Danyukova et al., 2018 [91] |
Loss of PGRN/CLN11 function | Sample | Affected gene/protein | Reference |
PGRN/CLN11 (heterozygous mutation) | FTD patient fibroblasts | Reduced activity of CTSD/CLN10 | Ward et al., 2017 [92] |
PGRN/CLN11 (heterozygous mutation) | FTD patient iPSC-derived cortical neurons | Reduced activity of CTSD/CLN10 | Valdez et al., 2017 [80] |
PGRN/CLN11−/− | Liver, spleen, and brain samples from a PGRN/CLN11−/−mouse | Reduced activity of CTSD/CLN10 | Zhou et al., 2017 [79] |
Loss of ATP13A2/CLN12 function | Sample | Affected gene/protein | Reference |
ATP13A2/CLN12 knockdown | SH-SY5Y human neuroblastoma cells | Reduced amount and activity of CTSD/CLN10 | Matsui et al., 2013 [93] |